Glycogen storage disease type III medical therapy

Glycogen storage disease type III Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Glycogen storage disease type III from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Guidelines for Management
Case Studies
Case #1
Glycogen storage disease type III medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Glycogen storage disease type III medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Glycogen storage disease type III medical therapy
CDC on Glycogen storage disease type III medical therapy
Glycogen storage disease type III medical therapy in the news
Blogs on Glycogen storage disease type III medical therapy
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Glycogen storage disease type III medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Medical Therapy

• The primary concern in infants and young children with GSD type 3 is hypoglycemia.
• However hypoglycemic episodes are less marked in glycogen storage disease type 3 than glycogen storage disease type 1.
• A high protein diet is recommended, especially for children with growth failure and myopathy due to reasons including:
  • Protein provides alanine which may be used in gluconeogenesis as a substitute source of glucose during fast.
  • High dietary protein increase synthesis of proteins in muscles and improves muscle function.
  • Replacement of carbohydrates with protein reduces storage of glycogen.
• A low fat diet is recommended due to reasons including:
  • High protein and high carbohydrates necessitate reduction of fats.
  • Young age group individuals may be inefficient in oxidizing long chain fatty acids.
  • Moderate amount of medium chain triglycerides (MCT) are preferred as they are ketogenic and may provide additional energy source for brain.
• It is not needed to avoid sucrose (fructose and glucose) and lactose (galactose and glucose).
• A metabolic dietician should be consulted once a case of GSD type 3 is diagnosed.
• Distribution of calories:
  • Calories from carbohydrate: 35-55%
  • Calories from protein: 20-30%
  • Calories from fats: 20-35 (including MCT)

Nutritional therapy

• 1 Infants or young child
  • 1.1 Asymptomatic or mild hypoglycemia

    • Preferred treatment (1): Cornstarch (CS) 1 g/kg body weight PO q4h

    NOTE (1): Digestive enzymes such as amylase are not fully functional during infancy. So, CS may not be well tolerated leading to gas, diarrhea, and bloating. Addition of pancrelipase with CS may help with digestion and reduces side effects.

    NOTE (2): Pancrealipase consists of three enzymes including lipase, protease, and amylase.

    NOTE (3): Typically, CS requirement of glycogen storage disease type 3 is less than glycogen storage disease type 1. So, starting CS at a lower dose and increasing the dose as per requirement is recommended.

    NOTE (4): During the initiation of treatment, blood glucose should be monitored every hour to establish the adequacy of CS dosage. As the dosage of CS is fixed, the frequency of blood glucose monitoring may be decreased thereafter.

    NOTE (5): Careful monitoring of blood glucose is needed during:

    • Illness
    • Diet or schedule is changed
    • During start of exercise routine
    • Randomly to detect asymptomatic hypoglycemia

  • 1.2 Severe hypoglycemia

    • Preferred treatment (1): Cornstarch (CS) 1.6 g/kg body weight PO q4h
    • Preferred treatment (2): Overnight gastric feedings (OGFs)

• 2 Older child
  • 2.1 Asymptomatic or mild hypoglycemia

    • Preferred treatment (1): Cornstarch (CS) 1 g/kg body weight PO q4h

  • 2.2 Severe hypoglycemia

    • Preferred treatment (1): Cornstarch (CS) 1.7–2.5 g/kg body weight PO q6h

• 3 Adults
  • Glycogen stirage disease type 3a

    • Increase protein in diet

  • Glycogen stirage disease type 3b

    • No specific treatment is needed